Contact
Get in touch with Unguard Therapeutics
We welcome inquiries from partners, investors, and collaborators.
Investment highlights
- First-in-class mechanism targeting uracil excision
- Strong IP strategy and patent filings
- Backed by Institut Curie discoveries
- Addressing a major unmet need (PARPi resistance)
- Multi-billion € market potential
Market opportunity
HRD cancers represent a significant
and growing market across multiple indications:
- Ovarian cancer
- Breast cancer
- Prostate cancer
- Pancreatic cancer
Get in touch with
Unguard Therapeutics
We welcome inquiries from partners, investors, and collaborators.
General inquiries: contact@unguardtx.com
Business / partnering: bd@unguardtx.com
Investors relations: investors@unguardtx.com
